407 related articles for article (PubMed ID: 30093322)
1. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].
Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS
An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322
[TBL] [Abstract][Full Text] [Related]
2. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
3. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
Guimbellot JS; Baines A; Paynter A; Heltshe SL; VanDalfsen J; Jain M; Rowe SM; Sagel SD;
J Cyst Fibros; 2021 Mar; 20(2):213-219. PubMed ID: 33249004
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
[TBL] [Abstract][Full Text] [Related]
5. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
6. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
7. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
Salvatore D; Carnovale V; Iacotucci P; Braggion C; Castellani C; Cimino G; Colangelo C; Francalanci M; Leonetti G; Lucidi V; Manca A; Vitullo P; Ferrara N
Pediatr Pulmonol; 2019 Sep; 54(9):1398-1403. PubMed ID: 31237430
[TBL] [Abstract][Full Text] [Related]
8. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.
Guimbellot J; Solomon GM; Baines A; Heltshe SL; VanDalfsen J; Joseloff E; Sagel SD; Rowe SM;
J Cyst Fibros; 2019 Jan; 18(1):102-109. PubMed ID: 29685811
[TBL] [Abstract][Full Text] [Related]
10. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
[TBL] [Abstract][Full Text] [Related]
11. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
[TBL] [Abstract][Full Text] [Related]
12. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.
Bernarde C; Keravec M; Mounier J; Gouriou S; Rault G; Férec C; Barbier G; Héry-Arnaud G
PLoS One; 2015; 10(4):e0124124. PubMed ID: 25853698
[TBL] [Abstract][Full Text] [Related]
13. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
14. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
15. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
[TBL] [Abstract][Full Text] [Related]
16. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
Ramsey BW; Davies J; McElvaney NG; Tullis E; Bell SC; Dřevínek P; Griese M; McKone EF; Wainwright CE; Konstan MW; Moss R; Ratjen F; Sermet-Gaudelus I; Rowe SM; Dong Q; Rodriguez S; Yen K; Ordoñez C; Elborn JS;
N Engl J Med; 2011 Nov; 365(18):1663-72. PubMed ID: 22047557
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
Davies JC; Wainwright CE; Canny GJ; Chilvers MA; Howenstine MS; Munck A; Mainz JG; Rodriguez S; Li H; Yen K; Ordoñez CL; Ahrens R;
Am J Respir Crit Care Med; 2013 Jun; 187(11):1219-25. PubMed ID: 23590265
[TBL] [Abstract][Full Text] [Related]
18. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.
Volkova N; Moy K; Evans J; Campbell D; Tian S; Simard C; Higgins M; Konstan MW; Sawicki GS; Elbert A; Charman SC; Marshall BC; Bilton D
J Cyst Fibros; 2020 Jan; 19(1):68-79. PubMed ID: 31196670
[TBL] [Abstract][Full Text] [Related]
19. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
[TBL] [Abstract][Full Text] [Related]
20. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
[No Abstract] [Full Text] [Related]
[Next] [New Search]